BioSpace News Archive

Kodiak Sciences Inc. announced that three scientific presentations on tarcocimab tedromer, including a first-time presentation of the primary results from the Phase 3 DAYLIGHT study in wet age-related macular degeneration.

Immunic, Inc. announced that Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, presented data from the company’s phase 2 EMPhASIS trial of nuclear receptor related 1 activator, vidofludimus calcium, in relapsing-remitting multiple sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting, taking place October 11-13 in Milan, Italy.

PolyPid Ltd. announced that it has received a written notice from The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550, which requires listed securities, including the Company’s ordinary shares, to maintain a minimum bid price of $1.00 per share.

Tiziana Life Sciences Ltd. announced a late breaking poster titled, “Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody : Safety, Biomarker, And Disability Outcomes”, will be presented at the 39th Congress of the European Committee for Treatment and Research of Multiple Sclerosis being held in Milan, Italy, October 11-13, 2023.

AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its robust portfolio and pipeline at the European Society for Medical Oncology Congress, October 20-24, 2023.

BridgeBio Pharma, Inc. today announced that on October 06, 2023, the compensation committee of BridgeBio’s board of directors granted nineteen new employees restricted stock units for an aggregate of 227,507 shares of the Company’s common stock.

Matinas BioPharma announces complete clinical resolution of a patient’s recurrent hemorrhagic cystitis due to Candida krusei, a fluconazole inherited resistant fungal pathogen, following treatment with MAT2203, Matinas’ oral formulation of the potent antifungal amphotericin B.

Vivos Therapeutics, Inc. announced that its flagship daytime-nighttime appliance (DNA) will be tested in a clinical trial at Stanford Medicine.

ImmPACT Bio USA , Inc. today announced that it will participate at the BIO Investor Forum, to be held from October 17-18, 2023 in San Francisco, CA.

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced top-line findings from a recent subgroup analysis of AspyreRx (formerly BT-001) in its pivotal trial for type 2 diabetes (T2D).